News

Public · Published

AVBP: ARR-217 achieved a 44.8% ORR at 6 mg/kg in heavily pretreated metastatic CRC

ArriVent Biopharma reported that ARR-217 achieved a 44.8% objective response rate and 93.1% disease control rate at 6 mg/kg in heavily pretreated metastatic colorectal cancer, with mostly low-grade toxicity and 2% Grade 3 diarrhea.

Published:

Updated:

What happened

ArriVent Biopharma reported that ARR-217 achieved a 44.8% objective response rate and 93.1% disease control rate at 6 mg/kg in heavily pretreated metastatic colorectal cancer, with mostly low-grade toxicity and 2% Grade 3 diarrhea.

Confirmed

Global impact / market context

Positive early data could make ARR-217 a valuable treatment candidate in colorectal cancer, a large market. ArriVent must still fund Phase Ib studies and a planned Phase III trial, so success would affect future capital spending and potential revenue.

Analyst inference

The results are early-stage, from a small study with Phase III start targeted by end-2027, so they carry high development risk. Investors weigh promising response rates against the long, costly path to approval and commercial competition.

Analyst inference

What to watch

  1. Phase Ib monotherapy and combination studies are continuing, which means researchers are still testing dosing and pairing ARR-217 with other treatments before larger trials. Confirmed
  2. ArriVent targets starting a Phase III trial by end-2027, which means a large late-stage study to confirm benefits before seeking regulatory approval. Proposed
  3. Watch for updated efficacy and safety data from ongoing Phase Ib studies, since durable responses and manageable side effects would support moving ARR-217 into Phase III. Analyst inference

Evidence

  • Original source link unavailable